Stockscreener 앱 받기
7.16
2.05%
-0.15
시간 외 거래:
7.28
0.12
+1.68%
Artelo Biosciences Inc 주식(ARTL)의 최신 뉴스
Artelo Biosciences Enters Securities Purchase Agreements for Bridge Notes with Vanquish Funding Group and Boot Capital LLC - Minichart
Nano-cap Artelo Biosciences stock explodes — glaucoma study collaboration ignites rally - MSN
Artelo Biosciences Secures Bridge Financing Through Note Issuance - TipRanks
Artelo Biosciences Raises $310,000 in 12% Bridge Notes From Vanquish and Boot - TradingView
Artelo Biosciences (NASDAQ: ARTL) raises cash via 12% bridge notes - Stock Titan
Artelo Biosciences, Inc. 2025 Financial Results: Going Concern Risks, Capital Raises, and Significant Losses Detailed in Annual Report - Minichart
Small Cap Stocks To Watch NowMarch 18th - MarketBeat
Why Is Artelo Biosciences Stock Surging Today?Artelo Biosciences (NASDAQ:ARTL) - Benzinga
Artelo Biosciences completes 1-for-3 reverse stock split By Investing.com - Investing.com India
Artelo Biosciences (ARTL) Soars 40% After Securing Fully-Funded Glaucoma Trial Partnership - MEXC
Artelo Biosciences stock surges on glaucoma study agreement - Investing.com
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Artelo Biosciences moves into glaucoma research with fully funded clinical study - MSN
Artelo Biosciences (ARTL) Stock Jumps 40% on Surprise Glaucoma Study News - MEXC
Crude Oil Moves Higher; Jabil Shares Slide After Q2 Results - Benzinga
Artelo announces third-party fully funded clinical study agreement for ART27.13 - TipRanks
Artelo Biosciences’ Stock Increases with Positive R&D Updates - StocksToTrade
Artelo Biosciences jumps as it expands ART27.13 into glaucoma via fully funded clinical study - Quiver Quantitative
Artelo Biosciences (ARTL) Stock Rockets 40% Following Glaucoma Trial Partnership - parameter.io
Artelo Biosciences Shares Surge Amid Promising Research Updates - timothysykes.com
Dow Falls Over 150 POints; US Producer Prices Increase In February - Benzinga
Morning Market Movers: ARTL, SWMR, OVID, HIT See Big Swings - RTTNews
Artelo Biosciences (ARTL) Explores New Glaucoma Treatment in Upc - GuruFocus
Artelo Biosciences, Inc.Common Stock (NQ: ARTL - The Chronicle-Journal
Artelo Biosciences and Belfast Health and Social Care Trust Enter Definitive Investigator-Initiated Study Agreement - marketscreener.com
Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study - marketscreener.com
Glaucoma trial tests cannabinoid pill designed to protect vision - Stock Titan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Why Is ARTL Stock Soaring Pre-Market Today? - Stocktwits
Clinical Collaboration and Funding Arrangement: Artelo Biosciences, Inc. (NASDAQ: ARTL) announces the signing of a third-party fully funded clinical research agreement to advance the evaluation of its candidate drug ART27.13 in glaucoma patients. - Bitget
Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients - GlobeNewswire
Artelo Biosciences completes 1-for-3 reverse stock split - Investing.com
Artelo Biosciences Enacts Reverse Stock Split Amid Strain - TipRanks
Artelo Biosciences (NASDAQ: ARTL) posts loss and warns on going concern - Stock Titan
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Artelo Biosciences Stock Soars 114% After Promising Depression Treatment Data - MSN
Artelo Biosciences launches underwritten public offering to raise capital - MSN
ARTELO B: Target Price Consensus and Analysts Recommendations | ARTL | US04301G6070 - marketscreener.com
Artelo Biosciences, Inc. announced that it has received $0.3503 million in funding from Vanquish Funding Group Inc., Boot Capital LLC - marketscreener.com
Artelo Biosciences announces 3-for-1 reverse stock split - Yahoo Finance
Artelo Biosciences implements 3-for-1 reverse stock split By Investing.com - Investing.com Australia
Aug PostEarnings: Is Artelo Biosciences Inc forming a bullish divergenceJuly 2025 Retail & Weekly High Momentum Picks - baoquankhu1.vn
Rate Hike: Is Artelo Biosciences Inc forming a bullish divergence2025 Big Picture & Fast Moving Trade Plans - baoquankhu1.vn
Artelo Biosciences announces reverse stock split - MSN
Artelo Biosciences implements 3-for-1 reverse stock split - Investing.com
Artelo Biosciences (Nasdaq: ARTL) plans 3-for-1 reverse stock split in March 2026 - Stock Titan
Artelo Biosciences Announces 3-for-1 Reverse Stock Split to Enhance Share Price and Marketability - Quiver Quantitative
Artelo Biosciences Announces Reverse Stock Split - TradingView
Artelo shrinks share count to 708K in 3-for-1 reverse split - Stock Titan
ARTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ARTL SEC FilingsArtelo Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ARTL PE Ratio & Valuation, Is ARTL Overvalued - Intellectia AI
Artelo Biosciences, Inc. Announces Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Artelo Biosciences (ARTL) Reports Key Advances and Financial Res - GuruFocus
Artelo Biosciences reports $12.9M loss for 2025 - Investing.com South Africa
ARTL: Strong clinical advances offset by higher net loss and lower cash reserves in 2025 - TradingView
Artelo Biosciences (NASDAQ: ARTL) outlines oncology and neuropathy drug pipeline - Stock Titan
ARTL: Net loss increased to $12.9 million in 2025, with urgent need for new funding to sustain operations - TradingView
Artelo Biosciences Provides Business Update Highlighting - GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga
Artelo Biosciences reports $12.9M loss for 2025 By Investing.com - Investing.com India
Artelo Biosciences (NASDAQ:ARTL) Trading Down 6.1% – What’s Next? - Defense World
Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results - Bitget
1.20%
0.06%
자본화:
|
볼륨(24시간):